Cargando…

The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity

N(6)-methyladenosine (m(6)A) is the most prevalent posttranscriptional modification on RNA. NK cells are the predominant innate lymphoid cells that mediate antiviral and antitumor immunity. However, whether and how m(6)A modifications affect NK cell immunity remain unknown. Here, we discover that YT...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Shoubao, Yan, Jiazhuo, Barr, Tasha, Zhang, Jianying, Chen, Zhenhua, Wang, Li-Shu, Sun, Joseph C., Chen, Jianjun, Caligiuri, Michael A., Yu, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225680/
https://www.ncbi.nlm.nih.gov/pubmed/34160549
http://dx.doi.org/10.1084/jem.20210279
_version_ 1783712133080416256
author Ma, Shoubao
Yan, Jiazhuo
Barr, Tasha
Zhang, Jianying
Chen, Zhenhua
Wang, Li-Shu
Sun, Joseph C.
Chen, Jianjun
Caligiuri, Michael A.
Yu, Jianhua
author_facet Ma, Shoubao
Yan, Jiazhuo
Barr, Tasha
Zhang, Jianying
Chen, Zhenhua
Wang, Li-Shu
Sun, Joseph C.
Chen, Jianjun
Caligiuri, Michael A.
Yu, Jianhua
author_sort Ma, Shoubao
collection PubMed
description N(6)-methyladenosine (m(6)A) is the most prevalent posttranscriptional modification on RNA. NK cells are the predominant innate lymphoid cells that mediate antiviral and antitumor immunity. However, whether and how m(6)A modifications affect NK cell immunity remain unknown. Here, we discover that YTHDF2, a well-known m(6)A reader, is upregulated in NK cells upon activation by cytokines, tumors, and cytomegalovirus infection. Ythdf2 deficiency in NK cells impairs NK cell antitumor and antiviral activity in vivo. YTHDF2 maintains NK cell homeostasis and terminal maturation, correlating with modulating NK cell trafficking and regulating Eomes, respectively. YTHDF2 promotes NK cell effector function and is required for IL-15–mediated NK cell survival and proliferation by forming a STAT5–YTHDF2 positive feedback loop. Transcriptome-wide screening identifies Tardbp to be involved in cell proliferation or survival as a YTHDF2-binding target in NK cells. Collectively, we elucidate the biological roles of m(6)A modifications in NK cells and highlight a new direction to harness NK cell antitumor immunity.
format Online
Article
Text
id pubmed-8225680
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-82256802022-02-02 The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity Ma, Shoubao Yan, Jiazhuo Barr, Tasha Zhang, Jianying Chen, Zhenhua Wang, Li-Shu Sun, Joseph C. Chen, Jianjun Caligiuri, Michael A. Yu, Jianhua J Exp Med Article N(6)-methyladenosine (m(6)A) is the most prevalent posttranscriptional modification on RNA. NK cells are the predominant innate lymphoid cells that mediate antiviral and antitumor immunity. However, whether and how m(6)A modifications affect NK cell immunity remain unknown. Here, we discover that YTHDF2, a well-known m(6)A reader, is upregulated in NK cells upon activation by cytokines, tumors, and cytomegalovirus infection. Ythdf2 deficiency in NK cells impairs NK cell antitumor and antiviral activity in vivo. YTHDF2 maintains NK cell homeostasis and terminal maturation, correlating with modulating NK cell trafficking and regulating Eomes, respectively. YTHDF2 promotes NK cell effector function and is required for IL-15–mediated NK cell survival and proliferation by forming a STAT5–YTHDF2 positive feedback loop. Transcriptome-wide screening identifies Tardbp to be involved in cell proliferation or survival as a YTHDF2-binding target in NK cells. Collectively, we elucidate the biological roles of m(6)A modifications in NK cells and highlight a new direction to harness NK cell antitumor immunity. Rockefeller University Press 2021-06-23 /pmc/articles/PMC8225680/ /pubmed/34160549 http://dx.doi.org/10.1084/jem.20210279 Text en © 2021 Ma et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Ma, Shoubao
Yan, Jiazhuo
Barr, Tasha
Zhang, Jianying
Chen, Zhenhua
Wang, Li-Shu
Sun, Joseph C.
Chen, Jianjun
Caligiuri, Michael A.
Yu, Jianhua
The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity
title The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity
title_full The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity
title_fullStr The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity
title_full_unstemmed The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity
title_short The RNA m(6)A reader YTHDF2 controls NK cell antitumor and antiviral immunity
title_sort rna m(6)a reader ythdf2 controls nk cell antitumor and antiviral immunity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225680/
https://www.ncbi.nlm.nih.gov/pubmed/34160549
http://dx.doi.org/10.1084/jem.20210279
work_keys_str_mv AT mashoubao thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT yanjiazhuo thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT barrtasha thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT zhangjianying thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT chenzhenhua thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT wanglishu thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT sunjosephc thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT chenjianjun thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT caligiurimichaela thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT yujianhua thernam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT mashoubao rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT yanjiazhuo rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT barrtasha rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT zhangjianying rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT chenzhenhua rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT wanglishu rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT sunjosephc rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT chenjianjun rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT caligiurimichaela rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity
AT yujianhua rnam6areaderythdf2controlsnkcellantitumorandantiviralimmunity